ALLMedicine™ Schizoaffective Disorder Center

Feb 19th, 2021 - Patients with psychotic spectrum disorders (PSD) exhibit similar patterns of atrophy and microstructural changes that may be associated with common symptomatology (e.g., symptom burden and/or cognitive impairment). Gray matter concentration values...

Feb 15th, 2021 - Excessive energy intake likely favors metabolic dysfunction in patients with schizophrenia and may be, in part, the consequence of antipsychotic treatments. However, previous studies on the prevalence of bulimia and binge eating symptoms in antips...

Feb 13th, 2021 - Patients with psychiatric disorders often have cognitive impairment. Several deficits have been recognized in patients with mood and/or psychotic disorders. We hypothesized that differences in the levels of deterioration exist between patients wit...

Feb 3rd, 2021 - To investigate the long-term real-world effectiveness of antipsychotics and other psychopharmacotherapies in the treatment of schizoaffective disorder (SCHAFF). Two nationwide cohorts of SCHAFF patients were identified from Finnish and Swedish reg...

Feb 2nd, 2021 - To investigate the feasibility and acceptability of using liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis. A double-blind, randomized, placebo-...

Feb 19th, 2021 - Patients with psychotic spectrum disorders (PSD) exhibit similar patterns of atrophy and microstructural changes that may be associated with common symptomatology (e.g., symptom burden and/or cognitive impairment). Gray matter concentration values...

Feb 15th, 2021 - Excessive energy intake likely favors metabolic dysfunction in patients with schizophrenia and may be, in part, the consequence of antipsychotic treatments. However, previous studies on the prevalence of bulimia and binge eating symptoms in antips...

Feb 13th, 2021 - Patients with psychiatric disorders often have cognitive impairment. Several deficits have been recognized in patients with mood and/or psychotic disorders. We hypothesized that differences in the levels of deterioration exist between patients wit...

Feb 8th, 2021 - Clozapine tablets are an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study ( 1.1, 14.1). Reducing suicidal behavior in patients with schizophrenia or schizoaffective dis...

Feb 3rd, 2021 - To investigate the long-term real-world effectiveness of antipsychotics and other psychopharmacotherapies in the treatment of schizoaffective disorder (SCHAFF). Two nationwide cohorts of SCHAFF patients were identified from Finnish and Swedish reg...

Feb 20th, 2020 - Tardive dyskinesia (TD) is a troubling side effect that may occur with long-term dopaminergic antagonist medications. TD manifests as involuntary movements of the tongue, lips, face, trunk, and extremities. It is most commonly seen in patients wit...

Feb 20th, 2020 - Tardive dyskinesia (TD) is a troubling side effect that may occur with long-term dopaminergic antagonist medications. TD manifests as involuntary movements of the tongue, lips, face, trunk, and extremities. It is most commonly seen in patients wit...

Oct 10th, 2019 - Clozapine is an atypical antipsychotic that the US Food and Drug Administration (FDA) approved for use in schizophrenia and suicidality associated with schizophrenia or schizoaffective disorder. Clozapine has been shown to be superior to other ant.

Jun 3rd, 2019 - SAN FRANCISCO – Assessing the impact of tardive dyskinesia on the lives of patients requires more than just visual observation, Stanley N. Caroff, MD, said at the annual meeting of the American Psychiatric Association.

Apr 29th, 2019 - Tardive dyskinesia (TD) is a movement disorder caused by the long-term use of dopaminergic antagonists or other antipsychotic medications. Patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have a history of long-term u...